TY - JOUR
T1 - Incidence of frontotemporal disorders in Olmsted County
T2 - A population-based study
AU - Turcano, Pierpaolo
AU - Stang, Cole D.
AU - Mielke, Michelle M.
AU - Martin, Peter R.
AU - Upadhyaya, Sudhindra G.
AU - Josephs, Keith A.
AU - Boeve, Bradley F.
AU - Knopman, David S.
AU - Petersen, Ronald C.
AU - Savica, Rodolfo
N1 - Funding Information:
The authors thank Lea Dacy for proof-reading and formatting assistance. This study was supported by award R01 AG034676 from the National Institute on Aging of the National Institutes of Health and by the Mayo Foundation for Medical Education and Research. The funding sources had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Dr. Turcano and Messrs Stang, Martin, and Upadhyaya had no conflict of interest. Dr. Mielke received funding from the National Institutes of Health, and unrestricted research grants from Biogen and Lundbeck; she has consulted for Lysosomal Therapeutics, Inc, and Eli Lilly. Dr. Josephs received funding from the National Institute on Aging, the National Institute on Deafness and Other Communication Disorders, and the National Institute of Neurological Disorders and Stroke. Dr. Boeve received funding from the National Institute on Aging, the National Institute of Neurological Disorders and Stroke, the Lewy Body Dementia Association, GE Healthcare, Axovant Sciences, Inc., and Biogen. Dr. Knopman served as a consultant to TauRx Pharmaceuticals ending in November 2012. Dr. Petersen reported grants from National Institute on Aging, during the conduct of the study; grants from National Institute on Aging, grants from Department of Defense, grants from Minnesota Partnership for Biotechnology and Medical Genomics, grants from PCORI, grants and other from Alzheimer's Association, grants from Abbott Laboratories, other from Dana Alliance for Brain Initiatives, other from Northwestern University, Alzheimer's Disease Center External Advisory Committee, other from Advisory Council on Research Care and Services, National Alzheimer's Project Act, other from French Foundation on Alzheimer's Disease, Scientific Steering Committee, French Ministry of Research, other from World Dementia Council, outside the submitted work; and Editorial Board Member of the following journals: Alzheimer's & Dementia; Alzheimer's Disease & Associated Disorders: An International Journal; Alzheimer's Research & Therapy. Dr. Savica received funding from the National Institute on Aging, the National Institute of Neurological Disorders and Stroke, and the Parkinson's Disease Foundation, Inc.
Funding Information:
The authors thank Lea Dacy for proof-reading and formatting assistance. This study was supported by award R01 AG034676 from the National Institute on Aging of the National Institutes of Health and by the Mayo Foundation for Medical Education and Research . The funding sources had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Publisher Copyright:
© 2019 the Alzheimer's Association
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Introduction: Frontotemporal dementia disorders (FTDs) are heterogeneous phenotypical behavioral and language disorders usually associated with frontal and/or temporal lobe degeneration. We investigated their incidence in a population-based cohort. Methods: Using a records-linkage system, we identified all patients with a diagnostic code for dementia in Olmsted County, MN, 1995–2010, and confirmed the diagnosis of FTD. A behavioral neurologist verified the clinical diagnosis and determined phenotypes. Results: We identified 35 FTDs cases. Overall, the incidence of FTDs was 4.3/100,000/year (95% CI: 2.9, 5.7). Incidence was higher in men (6.3/100,000, 95% CI 3.6, 9.0) than women (2.9/100,000; 95% CI: 1.3, 4.5); we observed an increased trend over time (B = 0.83, 95% CI: 0.54, 1.11, P <.001). At autopsy, clinical diagnosis was confirmed in eight (72.7%) cases. Discussion: We observed an increased incidence and trends of FTDs over time. This may reflect a better recognition by clinicians and improvement of clinical criteria and diagnostic tools.
AB - Introduction: Frontotemporal dementia disorders (FTDs) are heterogeneous phenotypical behavioral and language disorders usually associated with frontal and/or temporal lobe degeneration. We investigated their incidence in a population-based cohort. Methods: Using a records-linkage system, we identified all patients with a diagnostic code for dementia in Olmsted County, MN, 1995–2010, and confirmed the diagnosis of FTD. A behavioral neurologist verified the clinical diagnosis and determined phenotypes. Results: We identified 35 FTDs cases. Overall, the incidence of FTDs was 4.3/100,000/year (95% CI: 2.9, 5.7). Incidence was higher in men (6.3/100,000, 95% CI 3.6, 9.0) than women (2.9/100,000; 95% CI: 1.3, 4.5); we observed an increased trend over time (B = 0.83, 95% CI: 0.54, 1.11, P <.001). At autopsy, clinical diagnosis was confirmed in eight (72.7%) cases. Discussion: We observed an increased incidence and trends of FTDs over time. This may reflect a better recognition by clinicians and improvement of clinical criteria and diagnostic tools.
KW - Behavioral variant frontotemporal dementia
KW - Frontotemporal-dementia disorders (FTDs)
KW - Incidence
KW - Neurodegenerative dementia
KW - Population-based cohort
UR - http://www.scopus.com/inward/record.url?scp=85075904811&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075904811&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2019.08.199
DO - 10.1016/j.jalz.2019.08.199
M3 - Article
C2 - 31784373
AN - SCOPUS:85075904811
VL - 16
SP - 482
EP - 490
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
SN - 1552-5260
IS - 3
ER -